• Achieve Life Sciences presented 52-week safety results from its open-label ORCA-OL trial of cytisinicline at the American Thoracic Society 2026 meeting, completing the long-term safety package for its smoking-cessation New Drug Application.
• The study supported continued tolerability with no new safety concerns flagged over extended use in adults who smoke cigarettes, use e-cigarettes, or both.
• Side effects were largely mild to moderate, with relatively few participants stopping treatment due to adverse events.
• Additional cytisinicline data are scheduled for presentation at the meeting on May 20, including a comparative effectiveness analysis versus varenicline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605191415PRIMZONEFULLFEED9723084) on May 19, 2026, and is solely responsible for the information contained therein.